Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:G01N33/569

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/203828USE OF INHIBITOR IN PREPARATION OF DRUGS FOR TREATING SARS-COV-2 PNEUMONIA AND COMPLICATIONS THEREOF
WO 14.10.2021
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
Appl.No PCT/CN2021/075757 Applicant ACADEMY OF MILITARY MEDICAL SCIENCES, PLA Inventor WEI, Congwen
Provided is the use of an inhibitor in the preparation of drugs for treating SARS-CoV-2 pneumonia and complications thereof, wherein the inhibitor has one or more of the following properties: (1) reducing the binding of high-density lipoprotein to a receptor thereof; and (2) reducing the binding of the S protein of SARS-CoV-2 virus to cholesterol.
2.WO/2021/205058METHOD FOR DETERMINING CORONAVIRUS AND KIT FOR THE SAME
WO 14.10.2021
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/FI2021/050026 Applicant MEDICORTEX FINLAND OY Inventor HAREL, Adrian
The present invention relates to a method for detecting coronaviruses from samples wherein the detecting is performed in the aid of sialic acid and/or O-glycan binding lectins. According to one embodiment the method comprises subjecting the coronavirus (200) to a solution (201) comprising a component (202) adapted to neutralize the coronavirus and a component (203) adapted to expose glycoproteins of the coronavirus. When the sample comprises the virus, the exposed glycoproteins bind to a lectin (206) of a conjugate (204) to form a complex (208). Exposure of an immobilized lectin (209) to the complex gives rise to another complex (210) on detection zone (205b) of the probe. Signal derived from the signal generating means (207) in the detection zone is an indication of the presence of coronavirus. The method relates also to kits for use in the method.
3.WO/2021/205179MONOCYTE
WO 14.10.2021
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/GB2021/050869 Applicant UNIVERSITY OF SURREY Inventor ESTRADA, Fernando Oneissi Martinez
The invention relates to a novel pan-monocyte/pan-monocyte-derived cell biomarker and the use of an antibody immunospecific to the marker. The invention extends to methods for isolating and detecting human monocytes and monocyte-derived cells from biological samples, such as blood, based on the marker and the antibody.
4.WO/2021/206079MYCOPLASMA PNEUMONIAE IMMUNOASSAY METHOD AND IMMUNOASSAY INSTRUMENT
WO 14.10.2021
Int.Class C07K 16/44
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
44against material not provided for elsewhere
Appl.No PCT/JP2021/014591 Applicant DENKA COMPANY LIMITED Inventor KOHIYAMA, Risa
Disclosed is an immunoassay method that utilizes a monoclonal antibody which binds specifically to both a P1 protein and a P30 protein of Mycoplasma pneumoniae, the monoclonal antibody having a higher affinity to the P1 protein and the P30 protein of Mycoplasma pneumoniae than known monoclonal antibodies. The immonoassay method utilizes an antigen/antibody reaction between: a monoclonal antibody that reacts specifically with the P1 protein and the P30 protein derived from Mycoplasma pneumoniae and that further reacts specifically with a peptide containing an amino acid sequence comprising PPQPG or an antigen-binding fragment thereof; and the P1 protein and the P30 protein derived from Mycoplasma pneumoniae.
5.20210317193ANTIBODY SPECIFIC TO ALPHA-TOXIN OF STAPHYLOCOCCAL AUREUS AND USES THEREOF
US 14.10.2021
Int.Class C07K 16/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
12against material from bacteria
Appl.No 17211506 Applicant SYNERMORE BIOLOGICS (SUZHOU) CO., LTD. Inventor Tzu-Yuan CHAO

The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically bind to α-toxin of Staphylococcal aureus. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by Staphylococcal aureus infection in a subject in need, and a method for detecting α-toxin of Staphylococcal aureus in a sample.

6.WO/2021/204770PRO-ADRENOMEDULLIN FOR PROGNOSING DISEASE PROGRESSION IN SEVERE ACUTE RESPIRATORY SYNDROME (SARS)
WO 14.10.2021
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/EP2021/058885 Applicant B.R.A.H.M.S GMBH Inventor EBMEYER, Stefan
The invention relates to a method for prognosing disease progression in a patient that has or is at risk of developing a severe acute respiratory syndrome (SARS), wherein the method comprises determining a level of pro-adrenomedullin (proADM) or fragment(s) thereof in a sample from the patient, wherein said level indicates the severity of SARS progression. The method is in some embodiments configured for use when a patient exhibits symptoms of a severe acute respiratory syndrome (SARS), a patient exhibits symptoms of infection with a SARS-virus, the patient is infected with a SARS-virus, such as a SARS-coronavirus, such as SARS-CoV2.
7.WO/2021/204920DIAGNOSIS OF INFECTIONS WITH BURKHOLDERIA PSEUDOMALLEI (PATHOGEN OF MELIOIDOSIS) AND BURKHOLDERIA MALLEI (PATHOGEN OF GLANDERS)
WO 14.10.2021
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/EP2021/059128 Applicant SENOVA GESELLSCHAFT FÜR BIOWISSENSCHAFT UND TECHNIK MBH Inventor GAD, Anne-Marie
The present invention relates to methods for diagnosing infections with Burkholderia pseudomallei and/or Burkholderia mallei comprising the steps of - providing a patient serum sample containing antibodies, - bringing the serum sample into contact with at least two antigens selected from group A1 to A8, wherein • A1 is a peptide that has a sequence with at least 98% sequence homology to SEQ ID. No. 1, • A2 is a peptide that has a sequence with at least 98% sequence homology to SEQ ID. No. 2, • A3 is a peptide that has a sequence with at least 98% sequence homology to SEQ ID. No. 3, • A4 is a peptide that has a sequence with at least 98% sequence homology to SEQ ID. No. 4, • A5 is a peptide that has a sequence with at least 98% sequence homology to SEQ ID. No. 5, • A6 is a peptide that has a sequence with at least 98% sequence homology to SEQ ID. No. 6, • A7 is a peptide that has a sequence with at least 98% sequence homology to SEQ ID. No. 7, • A8 is a peptide that has a sequence with at least 98% sequence homology to SEQ ID. No. 8, - determining the binding of antibodies of the serum sample to the at least two antigens, wherein at least A3 is measured for the diagnosis of infections with Burkholderia mallei and at least A8 is measured for the diagnosis of infections with Burkholderia pseudomallei.
8.20210317410METHODS OF MAKING NATURAL KILLER CELLS AND USES THEREOF
US 14.10.2021
Int.Class C12N 5/0783
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
078Cells from blood or from the immune system
0783T cells; NK cells; Progenitors of T or NK cells
Appl.No 17058430 Applicant CoImmune, Inc. Inventor Mark DEBENEDETTE

The present invention relates to Natural Killer (“NK”) cells and uses thereof. In some embodiments NK cells are generated in vitro and used for adoptive transfer therapy. In some embodiments NK cells are generated in vivo to stimulate a patient's immune response.

9.WO/2021/205435HOME TESTING WITH CLOSED FEEDBACK LOOP AND CENTRAL EPIDEMIOLOGICAL MONITORING
WO 14.10.2021
Int.Class G16H 50/80
GPHYSICS
16INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
50ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
80for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
Appl.No PCT/IL2021/050377 Applicant RAPID BIO PASS LTD. Inventor TZIDON, Aviv
Medical test kits, systems and methods are provided for population-wide monitoring of medical states, and rapid, central closed loop testing with improved test development processes. Test utensils are configured to receive samples from users, carry out a medical testing of the samples and provide results that are sent to a central analysis unit that processes the results to deliver a related interpretation and/or instructions to the respective users. In such a way, the users so not merely receive raw test results, but explained interpretation accompanied by relevant behavioral instructions that optimize their coping with the medical state. On a management level, the accumulating data allows to derive epidemiological monitoring, to calculate unknown values of key parameters of pathogen spreading mechanisms and related immune responses, as well as to continuously improve the relatability and accuracy of the tests themselves.
10.20210318307PRECISION DIAGNOSIS OF CLOSTRIDIOIDES DIFFICILE INFECTION USING A SYSTEMS-BASED BIOMARKERS
US 14.10.2021
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No 17274529 Applicant Baylor College of Medicine Inventor Tor Savidge

Embodiments of the disclosure include methods and compositions related to accurate diagnosis and treatment of medical conditions having diarrhea as a symptom. In specific cases, the disclosure concerns accurate assessment of a diarrheal cause related to the presence or risk that may or may not be a pathogenic infection, such as a Clostridioides difficule infection (CDI). Particular embodiments encompass one or more specific features that provide information for accurate diagnosis and treatment of CDI versus another cause for diarrhea.